

Supplementary Material for

**X-ray crystallographic and kinetic studies of biguanide containing aryl sulfonamides as
Carbonic anhydrase inhibitors**

Chiara Baroni¹, Murat Bozdog², Gioele Renzi², Viviana De Luca³, Clemente Capasso³, Carla Bazzicalupi¹, Silvia Selleri², Marta Ferraroni¹, Fabrizio Carta², and Claudiu T. Supuran²

¹ Department of Chemistry “Ugo Schiff”, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino (FI), Italy;

² NEUROFARBA Department, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy


³ Department of Biology, Institute of Bioscience and Bioresources (IBBR)-CNR, via P. Castellino 111, 80131 Napoli (NA), Italy

*Corresponding author: (fabrizio.carta@unifi.it and marta.ferraroni@unifi.it)


Index

¹ H, ¹³ C, Spectra of compounds	S2-S4
Table S1. Summary of Data Collection and Refinement Statistics of hCA II- 5b , hCAII- 5b with glycerol and mimic-hCA XII- 5b	S5
Table S2. Summary of Data Collection and Refinement Statistics of hCA II- 5c	S6
Figure S1. The amino acid sequence of the hCA XII-mimic protein	S7


^1H NMR spectrum of compound **5a** (400 MHz, $\text{DMSO-}d_6$)




^{13}C NMR spectrum of compound **5a** (100 MHz, $\text{DMSO-}d_6$)




^1H NMR spectrum of compound **5b** (400 MHz, $\text{DMSO-}d_6$)



^{13}C NMR spectrum of compound **5b** (100 MHz, $\text{DMSO-}d_6$)



^1H NMR spectrum of compound **5c** (400 MHz, $\text{DMSO-}d_6$)



^{13}C NMR spectrum of compound **5c** (100 MHz, $\text{DMSO-}d_6$)




Table S1. Summary of Data Collection and Refinement Statistics Values in brackets refer to the highest resolution shell.

Data Collection statistics			
	CA II-5b	CAII-5b with glycerol	CA XII-5b
PDB ID	8ROU	8ROW	8RNS
Wavelength (Å)	1.0001	0.9718	1.0001
Space Group	P 2 ₁	P2 ₁	P 21
Unit cell (a, b, c, α, β, γ) (Å, °)	42.28 41.09 72.29 90 104.20 90	42.44 41.30 72.03 90 104.29 90	41.98 41.33 71.81 90 103.87 90
Limiting resolution (Å)	70.08-1.08 (1.10- 1.08)	40.02-1.05 (1.07- 1.05)	40.76-1.14 (1.16- 1.14)
Unique reflections	102568 (5042)	107024 (4661)	85727 (3897)
Rmerge	0.081 (1.403)	0.049 (0.706)	0.07 (1.351)
Rmeas	0.089 (1.591)	0.054 (0.801)	0.076 (1.547)
Redundancy	5.9 (4.5)	6.1 (4.5)	5.9 (4.3)
Completeness overall (%)	99.8 (99.7)	95.0 (83.7)	98.2 (90.0)
<I/σ(I)>	9.8 (1.1)	16.7 (2.2)	12.0 (1.1)
CC (1/2)	1.0 (0.3)	1.0 (0.7)	1.0 (0.4)
Refinement statistics			
Resolution range (Å)	70.08-1.08	40.02-1.05	40.76-1.14
Rfactor	0.1301	0.1160	0.1415
Rfree	0.1515	0.1386	0.1614
r.m.s.d. bonds (Å)	0.0118	0.0124	0.0113
r.m.s.d. angles (°)	1.8997	1.9011	1.7661
Ramachandran statistics (%)			
Most favored	97.3	97.3	96.9
additionally allowed	2.7	2.7	3.1
Outlier regions	0.0	0.0	0.0
Average B factor (Å²)			
All atoms	15.1	13.9	17.9
Inhibitors	14.6	13.6 / 23.1	23.5
Solvent	17.1	15.8	20.0

Table S2. Summary of Data Collection and Refinement Statistics Values in brackets refer to the highest resolution shell.

Data Collection statistics	
	CA II-5c
PDB ID	9H0V
Wavelength (Å)	1.0002
Space Group	P 21
Unit cell (a, b, c, α , β , γ) (Å,)	42.43 41.26 72.47 90 104.72 90
Limiting resolution (Å)	35.56-1.40 (1.42-1.40)
Unique reflections	43258 (2316)
Rmerge	0.040 (0.200)
Rmeas	0.044 (0.216)
Redundancy	6.2 (6.7)
Completeness overall (%)	90.3 (97.4)
$\langle I/\sigma(I) \rangle$	24.2 (8.6)
CC (1/2)	0.999 (0.981)
	Refinement statistics
Resolution range (Å)	35.56-1.40
Rfactor	0.0991
Rfree	0.1380
r.m.s.d. bonds (Å)	0.0105
r.m.s.d. angles ()	1.9264
	Ramachandran statistics (%)
Most favored	96.1
additionally allowed	3.9
Outlier regions	0.0
	Average B factor (Å²)
All atoms	16.8
Inhibitors	22.4 / 30.9
solvent	31.6

>hCA II

MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYR
LIQFHFHWGSLDGQGESEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGI FLKVGSAK PGLQKVVDVLD SIKTKGKSADFTNF
DPRGLLPESLDYWTYPGSLTTPPLECVTWIVLKEPISVSSEQVLKFRKLNFNNGEPEELMVDNWRPAQPLKNRQIKASFK

>hCA XII mimic

MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGH**SFKVNF**DDSQDKAVLKGGPLDGTYR
L**T**QFHFHWGSLDGQGESEHTVDKKKYAAELHLVHWNTKYGD**ASKAS**QQPDGLAVLGI FLKVGSAK PGLQKVVDVLD SIKTKGKSADFTNF
DPRGLLPESLDYWTYPGSLTTPPL**NET**VTWIVLKEPISVSSEQVLKFRKLNFNNGEPEELMVDNWRPAQPLKNRQIKASFK

hCA II	MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRIL	60
hCA XII	MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRIL	60
	NNGH AFNVE FDDSQDKAVLKGGPLDGTYR L IQFHFHWGSLDGQGESEHTVDKKKYAAELHL	120
	NNGH SFKVNF FDDSQDKAVLKGGPLDGTYR L TQFHFHWGSLDGQGESEHTVDKKKYAAELHL	120
	VHWNTKYGD FGKAV QQPDGLAVLGI FLKVGSAK PGLQKVVDVLD SIKTKGKSADFTNFDP	180
	VHWNTKYGD ASKAS QQPDGLAVLGI FLKVGSAK PGLQKVVDVLD SIKTKGKSADFTNFDP	180
	RGLLPESLDYWTYPGSLTTPPL LEC VTWIVLKEPISVSSEQVLKFRKLNFNNGEPEELM	240
	RGLLPESLDYWTYPGSLTTPPL NET VTWIVLKEPISVSSEQVLKFRKLNFNNGEPEELM	240
	VDNWRPAQPLKNRQIKASFK	260
	VDNWRPAQPLKNRQIKASFK	260

Figure S1. Amino acid sequence alignment of hCA II and hCA XII. Residues of hCA II bolded in red were replaced with the corresponding residues from hCA XII to create the mimic proteins.